Compare CG & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CG | HOLX |
|---|---|---|
| Founded | 1987 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Electronics |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 16.6B |
| IPO Year | 2012 | 1990 |
| Metric | CG | HOLX |
|---|---|---|
| Price | $57.12 | $74.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 15 |
| Target Price | $66.29 | ★ $79.64 |
| AVG Volume (30 Days) | 2.6M | ★ 2.9M |
| Earning Date | 10-31-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 445.01 | N/A |
| EPS | 1.78 | ★ 2.49 |
| Revenue | $3,208,300,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | N/A | $6.69 |
| Revenue Next Year | $20.80 | $5.74 |
| P/E Ratio | $32.05 | ★ $30.08 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $33.02 | $51.90 |
| 52 Week High | $69.85 | $80.31 |
| Indicator | CG | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 67.93 |
| Support Level | $53.25 | $74.55 |
| Resistance Level | $54.78 | $75.12 |
| Average True Range (ATR) | 1.55 | 0.28 |
| MACD | 0.79 | -0.14 |
| Stochastic Oscillator | 93.17 | 78.92 |
Carlyle Group is one of the world's largest alternative-asset managers, with $474.1 billion in total AUM, including $332.0 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, which includes its private equity, real estate, infrastructure, and natural resources offerings (with $163.5 billion in total AUM and $101.1 billion in fee-earning AUM), global credit ($208.5 billion/$167.2 billion), and investment/fund solutions, known as Carlyle AlphInvest ($102.1 billion/$63.7 billion). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 3,100 active carry fund investors from 87 countries.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.